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Background. Both plasma and mucosal levels of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1
(TIMP-1) have been shown to be independently correlated with ulcerative colitis (UC), but their relationship with each other
and to disease severity remains unclear. This study aims to evaluate the relationship between colonic mucosal and plasma levels
of MMP-1 and TIMP-1 with each other and with the severity of ulcerative colitis (UC). Methods. Colonic mucosal lesions and
venous blood samples were collected from 30 patients with UC and 15 normal subjects. Real-time reverse transcription-PCR and
immunohistochemistry were used to determine colonic mucosal MMP-1 and TIMP-1 expression; ELISA was used to measure
plasma levels of MMP-1 and TIMP-1. Results. Expression of colonic mucosal and plasma MMP-1 and TIMP-1 in patients with
UC was signiﬁcantly higher than that of controls (P<. 05), and was positively correlated with disease severity (P<. 05). Plasma
MMP-1 and TIMP-1 levels were well correlated with their corresponding expression in colonic mucosa (P<. 05, r = 0.805 and
0.908). Conclusion. Plasma MMP-1 and TIMP-1 levels reﬂect their colonic mucosal expression to some extent in patients with UC.
Plasma MMP-1 and TIMP-1, in particular, demonstrate the potential to become biomarkers to clinically diagnose UC, predict its
severity, and guide further therapy.
Copyright © 2009 Ying-De Wang et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Ulcerativecolitis(UC)isachronicnonspeciﬁcinﬂammatory
diseaseofthecolonwithunknownetiology.Nospeciﬁceﬀec-
tive treatment is available at present. Pathological colonic
lesions are usually limited to the mucosal and submucosal
areas,whilediarrhea,pusmucusbloodystool,andabdominal
pain are common clinical symptoms.
More attention is being focused on this disease because
its morbidity has increased in recent years in China, where
UC was once an uncommon gastrointestinal disorder. Pre-
vious studies on the pathogenesis of UC have shown that
colonic mucosal inﬂammation and ulceration are closely
related to the excessive degradation of extracellular matrix
(ECM) by matrix metalloproteinases (MMPs), which are
overexpressed and activated to cause colonic mucosal injury
and inﬂammation [1]. MMPs are a group of zinc-dependent
proteases that are produced and secreted by connective tissue
cells, endothelial cells, mono-macrophages, and other cells.
Their activity can be inhibited by their natural inhibitors—
tissue inhibitor of metalloproteinases (TIMPs). TIMPs are
a group of secretive glycoproteins that have the capacity to
inhibit MMP activity, thereby attenuating ECM degrada-
tion. TIMPs also participate in tissue structural modeling
and maintenance, and indirectly inﬂuence ECM-dependent
signal transduction. Four subtypes of TIMPs have been
identiﬁed in mammals: TIMP-1, TIMP-2, TIMP-3, and
TIMP-4. TIMP-1 is a soluble glycoprotein with a molecular
weightof29kD thatinhibits primarily MMP-1,MMP-3,and
MMP-9.
Animal and clinical studies have revealed the overex-
pression of various MMPs and TIMPs in the inﬂammatory
areas of colonic mucosa in UC; MMPs expression tend to
be particularly high. It is believed that increased ratio of
MMP/TIMP is one of the mechanisms in the pathogenesis
of UC [2–4]. MMP-1 and TIMP-1 are thought to be more
closely associated with UC than other MMPs and TIMPs;
studies [2, 5–7] have reported that their expression in2 Mediators of Inﬂammation
patients with UC is signiﬁcantly higher than in normal
control subjects. In particular, MMP-1 overexpression has
been correlated with mucosal inﬂammation and the initial
steps of ulceration. Furthermore, MMP-1 and TIMP-1 levels
in the peripheral blood were also found to be elevated
in patients with UC in studies by Wiercinska-Drapalo [8]
and Holten-Andersen[9]. However, the correlation between
plasma levels of these proteins and their mucosal expression
or with UC disease severity is not clear. In this study,
we examined MMP-1 and TIMP-1 expression both in the
colonic mucosa and plasma to study their relationship and
association with disease severity in patients with UC.
2.MaterialsandMethods
2.1. Patients and Samples. Thirty patients (male, n = 14;
female, n = 16; mean age, 46 years; age range, 23–73 years)
with UC diagnosed by clinical symptoms, endoscopy, and
pathology ﬁndings were enrolled in the study. Of the 30
patients, 4 patients had pan-colon lesions, 2 had semicolon
lesions, 17 had rectosigmoid lesions, and 7 had rectal lesions.
Patients were divided into groups based on the diagnostic
criteria of UC severity: 12 patients were classiﬁed as mild (M
group)and18classiﬁedasmoderate-to-severe(MTSgroup).
Meanwhile, 15 normal subjects were recruited as normal
controls (male, n = 6; female, n = 9; mean age, 41 years;
age range, 22–63 years).
Biopsy samples from mucosal lesions of UC patients
and normal mucosa of the normal control subjects were
divided into two parts. One part was immediately snap
frozen in liquid nitrogen and stored at −80◦Cf o rr e v e r s e
transcription- (RT-) PCR, and another part was ﬁxed in
formalin, embedded in paraﬃn, and cut into 4μm thick
sections for immunohistochemistry.
Blood was also drawn from both groups. The super-
natant was collected after spinning at 1000 × gf o r3 0
minutes, and then at 10000 × gf o r1 0m i n u t e sa t2 ◦Ct o8 ◦C
to remove blood platelets. Samples were stored at −80◦Cf o r
ELISA.
2.2. Total RNA Extraction. T o t a lR N Aw a se x t r a c t e df r o m
the frozen samples using an RNA isolation kit (Invitrogen,
Calif, USA) following the manufacturer’s instructions. RNA
integrity was assessed on a 1% agarose gel.
2.3. RT-PCR for MMP-1 and TIMP-1. RT-PCR was perfor-
med using the TaKaRa RNA PCR kit 3.0 (AMV; Dalian
Baosheng Biotechnology Company) following the manufac-
turer’s instructions. Primer sequences used in this study were
as follows:
MMP-1:
sense: 5 -ATGCGAACAAATCCCTTCTACC-3 ;
antisense: 5 -TTCCTCAGAAAGAGCAGCATCG-3 ;
TIMP-1:
sense: 5 -GGACACCAGAAGTCAACCAGACC-3 ;
antisense: 5 -CGTCCACAAGCAATGAGTGCC-3 .
β-actin (internal control):
sense: 5 -CCTTCCTGGGCATGGAGTCCTG-3 ,
antisense: 5 -GGAGCAATGATCTTGATCTTC-3 .
Reversetranscriptionwascarriedoutat30◦Cfor10min-
utes, 42◦C for 30 minutes, 99◦C for 5 minutes, and 5◦Cf o r5
minutes.PCRconditionswereasfollows:initialdenaturation
at 94◦C for 2 minutes, followed by 35 ampliﬁcation cycles
of 94◦C for 30 seconds, 53◦C for 30 seconds, at 72◦Cf o r1
minute, and extension at 72◦Cf o r1 0m i n u t e s .
Forsemiquantitativeanalysisofgeneexpression,ampliﬁ-
cation products were assessed on a 2% agarose gel. The band
density was determined by the Bio-imaging system (PALL
Company, USA). MMP-1 mRNA and TIMP-1 mRNA were
expressed by the ratios of MMP-1, TIMP-1, and β-actin OD
values.
2.4. Immunohistochemistry. After initial treatment, samples
were incubated with the primary antibodies, mouse anti-
human MMP-1 monoclonal antibody and mouse anti-
human TIMP-1 monoclonal antibody (Santa Cruz, USA),
at room temperature for approximately 1.5 hours. Sam-
ples were washed 3 times with PBS, then incubated with
a peroxidase-conjugated secondary antibody for 15 min-
utes, followed by washing with PBS. Samples were incu-
bated with the substrate diaminobenzidine (DAB) for 10
minutes.
Positive results of immunohistochemistry were deter-
mined by the appearance of brown or yellow DAB staining.
The Image-Pro-Plus 4.5 microscopic image analyzing system
was used to determine the intensity of staining. Five ﬁelds
in each section were randomly chosen, and the total optical
density and total image area were measured. The mean
optical density was calculated as the ratio of the total
optical density and total image area; larger mean optical
densities indicate greater expression of the corresponding
proteins.
2.5. ELISA. ELISA for plasma MMP-1 and TIMP-1 was per-
formed using an ELISA kit (R&D Systems, USA) following
the manufacturer’s instructions. Protein concentrations were
determined using a standard curve.
2.6. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n±
SD. Analyses of variance (ANOVA) with Student-Neuman-
Keuls post-hoc test were used to compare mRNA levels
of MMP-1 and TIMP-1 in patients with diﬀerent disease
severity. Spearman correlation analysis was used to deter-
mine the relationship between plasma and mucosal MMP-
1 and TIMP-1 levels. P<. 05 was considered statistically
signiﬁcant. All statistical analysis was performed using SPSS
11.5 for Windows.
3. Results
3.1.MMP-1andTIMP-1ExpressioninColonicMucosabyRT-
PCR. Colonic mucosal expressions of MMP-1 and TIMP-1
in UC patients were signiﬁcantly higher than those of in the
normal controls (P<. 05, Table 1). In addition, MMP-1 and
TIMP-1 expression increased with the severity of ulcerative
colitis (Table 1).
3.2. MMP-1 and TIMP-1 Expression in Colonic Mucosa by
Immunohistochemistry. Similar results were obtained withMediators of Inﬂammation 3
Table 1: MMP-1 levels in colonic mucosa and plasma.
Controls UC Mild Moderate-to-severe
(n = 12) (n = 30) (n = 12) (n = 18)
Colonicmucosa
RT-PCR
MMP-1 0.27 ± 0.04 0.63 ± 0.23∗ 0.46 ± 0.08∗ 0.80 ± 0.19∗
TIMP-1 0.51 ± 0.08 0.92 ± 0.24∗ 0.75 ± 0.14∗ 1.06 ± 0.22∗
Immunohistochemistry
MMP-1 0.005 ± 0.001 0.075 ± 0.003∗ 0.081 ± 0.003∗
TIMP-1 0.013 ± 0.003 0.080 ± 0.003∗ 0.090 ± 0.006∗
Plasma
ELISA
MMP-1 1.90 ± 0.37 2.46 ± 0.60∗ 2.21 ± 0.40 2.68 ± 0.68
TIMP-1 5.59 ± 0.30 6.37 ± 0.54∗ 6.14 ± 0.48∗ 6.60 ± 0.50∗
∗P <. 05 compared to controls
P<. 05 compared to M group
M1 2 3
(a)
M1 2 3
(b)
M123
(c)
Figure 1: RT-PCR results for MMP-1(A), TIMP-1(B), and β-actin(C): M, marker, lane 1, normal controls; lane 2, M group; lane 3, MTS
group.
immunohistochemistry. MMP-1 and TIMP-1 expression
levels in both the mild (M) and moderate-to-severe (MTS)
groups were signiﬁcantly higher than those of normal
controls (P<. 05), and they were expressed to a greater
extent in MTS group compared to M group (P<. 05;
Table 1; Figure 2).
3.3. MMP-1 and TIMP-1 Blood Level by ELISA Method. The
ELISA study (Table 1) showed that the overall plasma levels
of MMP-1 and TIMP-1 in UC patients were signiﬁcantly
higher than those of the control group (P<. 05). However,
no diﬀerence was observed between plasma MMP-1 levels
of patients with mild ulcerative colitis and normal controls
or between disease severity groups (MTS versus M group;
P>. 05 ). In contrast, plasma TIMP-1 levels in the MTS
group were signiﬁcantly higher than those of the M group
and signiﬁcantly higher in the M g r o u pc o m p a r e dt ot h e
normal controls (P<. 05).
3.4. Correlation Analysis of Plasma and Mucosal MMP-1
and TIMP-1 Levels. Plasma MMP-1 and TIMP-1 levels were
correlated with their colonic mucosal expression in UC
patients (MMP-1, P<. 05, r = 0.81; TIMP-1, r = 0.91;
Figures 3 and 4).
4. Discussion
In this study, we determined MMP-1 and TIMP-1 expression
levels in ulcerative colitis patients compared with normal
controls. Colonic mucosa expression was determined at the
mRNA and protein levels by RT-PCR and immunohisto-
chemistry. The corresponding plasma levels of MMP-1 and
TIMP-1 were determined using ELISA. Both MMP-1 and
TIMP-1 expression increased in the colonic mucosa of UC
patients compared to normal controls, and the expression
levels were correlated with disease severity. Similar ﬁndings
were found in the analysis of plasma. Plasma levels of
both MMP-1 and TIMP-1 correlated well with their colonic
mucosa levels. However, plasma TIMP-1 was well correlated
with disease severity, but plasma MMP-1 was not.
Our results are consistent with ﬁndings from McKaig
et al. [10] and supported previous studies demonstrating
that MMP-1 reﬂected acute tissue injury and was associated
withtheinitialstepsofulcerationinUCandnewbloodvessel
formation. [2, 4]V o nL a m p eBe ta l .[ 1] also showed that
TIMP-1 mRNA expression was 9- to 12-fold increased in UC
lesions.
MMP and TIMP expression increased not only in tissues
but also in the peripheral blood samples from patients4 Mediators of Inﬂammation
(a)
(b)
(c)
(d)
Figure 2: Immunohistochemistry showing MMP-1 expression in
(a) control group, (b) M group, and (c, d) MTS group: M, mild;
MTS, moderate-to-severe.
withacutecoronarysyndrome, cancer,hepatitis, rheumatoid
arthritis, and normal persons.[11–15] Wiercinska-Drapalo
A et al. [8] used ELISA to determine MMP-1 and TIMP-
1 expression and found that serum MMP-1 and TIMP-1
were signiﬁcantly increased in patients with UC compared
with normal controls. They also found that TIMP-1 level was
related to endoscopic mucosal injury, disease activity index,
clinical activity index, and C protein level although MMP-1
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Figure 3: Correlation between plasma and mucosal MMP-1
expression.
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Figure 4: Correlation between plasma and mucosal TIMP-1
expression.
was not. Our study produced similar ﬁndings; plasma MMP-
1 levels were higher in UC patients, but did not correlate
with disease severity. The plasma and mucosal TIMP-1 levels
were better indicators of disease severity. Further analyses of
plasma levels and mucosa expression revealed that plasma
levels of both MMP-1 and TIMP-1 correlated with mucosa
expression. These ﬁndings indicate that plasma MMP-1 and
TIMP-1 generally reﬂect the disease state, and TIMP-1 level
was additionally associated with disease severity.
MMP-1 is primarily associated with the initial steps
of ulceration in UC, [2, 4] which may explain its lack
of association with disease severity. In our study, most of
the patients were suﬀering from chronic recurrent UC, so
plasma MMP-1 could have been aﬀected. The ELISA assay
used in this study measures only free MMP-1 and MMP-1
combined with TIMP-1. Thus MMP-1 combined with α2 -
macroglobulin could not be detected. In addition, TIMP-
1 is more easily released into the blood; [15] therefore,
its measurement sensitivity is higher than that of MMP-1.Mediators of Inﬂammation 5
According to a previous study, [16] free MMP-1 decreased
and MMP-1 combined with TIMP-1 increased as the disease
progressed. This may be another reason why plasma MMP-
1 level increased only in moderate-to-severe disease patients,
but not in mild disease patients.
In conclusion, plasma MMP-1 and TIMP-1 reﬂect their
colonic mucosal expression to some extent; plasma TIMP-
1 reﬂects colonic mucosa lesion severity more sensitively
than plasma MMP-1 level. After excluding other diseases
such as coronary heart disease and liver disease that are also
associated with increased MMP-1 and TIMP-1 expressions,
plasma MMP-1 and TIMP-1, especially TIMP-1, could
possibly become useful biomarkers for UC diagnosis and
disease severity, and may be useful to guide therapy.
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